Multiple sclerosis is a complex, heterogeneous disorder of the CNS. The most common type of multiple sclerosis (MS) is relapsing-remitting; in which patients have episodes of worsening neurologic function, followed by full or partial recovery. Treatment with disease-modifying therapies decreases frequency and severity of relapses and reduces brain lesion development, which in turn may slow disease progression. The Medical Advisory Board of the National Multiple Sclerosis Society recommends that treatment with one of these agents should begin immediately after a definitive diagnosis of relapsing-remitting MS (RRMS) and may also be considered for selected patients with a first attack who are at high risk of MS. Treatment should be continued indefinitely unless there is poor effectiveness or tolerability MerriKay Oleen-Burkey, Examining the Influence of Behavioral Factors on Compliance and Persistence with Glatiramer Acetate Injection for Relapsing-Remitting Multiple Sclerosis.
Journal of Multiple sclerosis publishes video articles containing multiple sclerosis therapies mainly focussing on the rehabilitation of multiple sclerosis. Since the disease causes various physical disabilities there are various physical therapies and inpatient programmes being followed in various multiple sclerosis treatment centres. These video articles mainly focus on the betterment of patient during this cause of period.
Last date updated on October, 2020